| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 159.76M | 164.26M | 158.65M | 137.64M | 110.58M | 104.54M |
| Gross Profit | 61.19M | 65.82M | 61.19M | 48.80M | 48.21M | 44.92M |
| EBITDA | 15.58M | 17.19M | 21.34M | -59.70M | 7.32M | 10.58M |
| Net Income | 5.34M | 5.65M | 3.60M | -75.17M | -3.85M | 13.90M |
Balance Sheet | ||||||
| Total Assets | 213.87M | 225.89M | 233.41M | 215.43M | 281.19M | 294.07M |
| Cash, Cash Equivalents and Short-Term Investments | 24.24M | 20.75M | 14.04M | 9.99M | 8.20M | 8.63M |
| Total Debt | 39.71M | 43.10M | 49.76M | 50.38M | 45.55M | 57.70M |
| Total Liabilities | 80.19M | 88.83M | 98.75M | 84.96M | 75.83M | 85.61M |
| Stockholders Equity | 133.68M | 137.07M | 134.66M | 130.47M | 205.36M | 208.46M |
Cash Flow | ||||||
| Free Cash Flow | 15.11M | 16.22M | 8.15M | 280.00K | 14.07M | 1.14M |
| Operating Cash Flow | 19.98M | 21.53M | 13.05M | 4.89M | 19.07M | 11.31M |
| Investing Cash Flow | -4.87M | -5.31M | -7.45M | -5.39M | -7.36M | -23.98M |
| Financing Cash Flow | -10.82M | -9.66M | -2.56M | 1.48M | -12.89M | -10.78M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €301.65M | 14.57 | 5.62% | 6.66% | 5.75% | 8.26% | |
66 Neutral | €110.50M | 4.41 | 17.82% | 4.15% | -5.58% | 165.78% | |
65 Neutral | €58.43M | 10.46 | ― | 3.58% | ― | ― | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
47 Neutral | €39.77M | -0.98 | -51.98% | ― | -23.11% | -284.12% |
Cellularline S.p.A. reported a slight decrease in consolidated revenues to €113.2 million for the first nine months of 2025, compared to the same period in 2024, due to challenging international market conditions. Despite this, the company managed to reduce its net financial debt significantly and maintained a solid financial position. The domestic market showed resilience with growth in the Red Line product category, while international markets faced a slowdown. The company continues to focus on cost optimization and strategic partnerships to enhance its market position and generate sustainable value for stakeholders.
The most recent analyst rating on (IT:CELL) stock is a Hold with a EUR3.00 price target. To see the full list of analyst forecasts on Cellularline SpA stock, see the IT:CELL Stock Forecast page.
Cellularline S.p.A. announced that Mauro Borgogno, the Group Chief Financial Officer and Executive responsible for corporate accounting documents, will step down from his roles effective December 1, 2025, due to personal reasons and a reduction in professional commitments. Borgogno will continue to serve as an administrator of the company, ensuring operational continuity until his departure. The company will announce a successor in due course, highlighting the importance of a smooth transition for maintaining its market position.
The most recent analyst rating on (IT:CELL) stock is a Hold with a EUR3.00 price target. To see the full list of analyst forecasts on Cellularline SpA stock, see the IT:CELL Stock Forecast page.